98%
921
2 minutes
20
Cryoablation is gaining attention as a minimally invasive treatment option for prostate cancer (PCa), offering a balance between effective oncological control and preserving genitourinary functions and quality of life. Focal cryoablation is emerging as a viable option for patients with PCa, particularly those who prioritize functional outcomes such as erectile functions and urinary continence. Whole-gland cryoablation, on the contrary, may be more appropriate for intermediate- and high-risk PCa where complete ablation of the prostate is necessary to ensure oncological control. Despite promising results, there is considerable heterogeneity in the available data regarding the long-term oncological and functional outcomes of cryoablation techniques, making it premature to issue definitive treatment recommendations. Further studies, particularly randomized controlled trials, are needed to clarify the role of cryoablation in PCa treatment. This narrative review aims to present the most relevant and up-to-date evidence on both focal and whole-gland cryoablation in PCa, providing a comprehensive overview of their current clinical applications, outcomes, and future potential.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227874 | PMC |
http://dx.doi.org/10.1177/11795549251350830 | DOI Listing |
J Environ Pathol Toxicol Oncol
January 2025
Department of Biostatistics, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.
Prostate cancer and inflammation mechanism are closely related because chronic inflammation causes inflammatory cells to infiltrate into prostatic atrophy areas and proliferative inflammatory atrophy is accepted as the initiator of prostate cancer. The study included 90 patients (28 patients with benign prostatic hyperplasia (BPH), 35 patients with localized prostate cancer (LPCa), and 27 patients with metastatic prostate cancer (MPCa) and 90 healthy controls. Blood samples from 90 patients and 90 healthy people were used to isolate genomic DNA.
View Article and Find Full Text PDFCrit Rev Ther Drug Carrier Syst
January 2025
Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Cancer stem cells (CSCs) are a category of cancer cells endowed with the ability to renew themselves, undergo unregulated growth, and exhibit a differentiation capacity akin to that of normal stem cells. CSCs have been linked with tumor metastasis and cancer recurrence due to their ability to elude immune monitoring. As a result, targeting CSCs specifically may improve the efficacy of cancer therapy.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Department of Urology, Center for Health Outcomes Research and Dissemination, University of Washington, Seattle.
Importance: Black individuals have a twofold higher rate of prostate cancer death in the US compared with the average population with prostate cancer. Few guidelines support race-conscious screening practices among at-risk Black individuals.
Objective: To examine structural factors that facilitate or impede access to prostate cancer screening among Black individuals in the US.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFEndocr Relat Cancer
September 2025
Department of Molecular, Cell and Developmental Biology, University of California Los Angeles;Los Angeles, CA 90095.
Age is a major risk factor for a range of diseases including prostate cancer. Understanding how age influences the susceptibility of normal prostate epithelial cells to cancer initiation is complicated by the fact that aging affects all tissues in the body. Assessing how various aging mechanisms influence the prostate epithelium is a necessary step to determine the critical factors associated with aging that increase prostate cancer risk.
View Article and Find Full Text PDF